The therapeutic management of differentiated thyroid cancer

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 15, 2008, Pages 2627-2637

  Sipos, Jennifer A ^a   Mazzaferri, Ernest L ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Differentiated thyroid cancer; Follicular thyroid cancer; Papillary thyroid cancer; Thyroid cancer; Treatment

Indexed keywords

ANGIOGENESIS INHIBITOR; B RAF KINASE; CALVASCULIN; CYCLOOXYGENASE 2 INHIBITOR; GELDANAMYCIN; IMMUNOMODULATING AGENT; IODINE 123; IODINE 131; LEVOTHYROXINE; LIOTHYRONINE; LITHIUM CARBONATE; PLACEBO; PREDNISONE; PROTEIN PATCHED; PROTEIN RET; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; RETINOID; THYROGLOBULIN; THYROTROPIN;

AGE; AGEUSIA; AIRWAY OBSTRUCTION; BLEEDING; BONE PAIN; BONE TURNOVER; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE MARKER; DOSE RESPONSE; DOSIMETRY; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RETENTION; DRUG TARGETING; EDEMA; FOLLOW UP; HUMAN; HYPOPARATHYROIDISM; INTERDISCIPLINARY COMMUNICATION; LACRIMAL DUCT OCCLUSION; LEUKOPENIA; LOW DRUG DOSE; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; NAUSEA; NECK DISSECTION; PAIN; PAROTITIS; PATIENT SAFETY; PRACTICE GUIDELINE; PROGNOSIS; RADIATION SICKNESS; RADIOISOTOPE THERAPY; RECURRENCE RISK; RECURRENT LARYNGEAL NERVE PALSY; REVIEW; SIDE EFFECT; SUBTOTAL THYROIDECTOMY; SURGICAL TECHNIQUE; SWELLING; THROMBOCYTOPENIA; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROID SCINTISCANNING; THYROIDECTOMY; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR RECURRENCE; VOMITING; XEROSTOMIA;

CELL DIFFERENTIATION; COMBINED MODALITY THERAPY; HORMONE REPLACEMENT THERAPY; HUMANS; LYMPH NODE EXCISION; POSTOPERATIVE COMPLICATIONS; RADIOTHERAPY DOSAGE; THYROID HORMONES; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN;

EID: 55249110867     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.15.2627     Document Type: Review

References (102)

1. Cady B. Our AMES is true: how an old concept still hits the mark: or, risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer. Am J Surg 1997;174:462-8
2. Schlumberger MJ. Medical progress - papillary and follicular thyroid carcinoma. N Engl J Med 1998;338:297-306
3. Duren M, Yavuz N, Bukey Y, et al. Impact of initial surgical treatment on survival of patients with differentiated thyroid cancer: experience of an endocrine surgery center in an iodine-deficient region. World J Surg 2000;24(11):1290-4
4. Mazzaferri EL. Thyroid carcinoma: papillary and follicular. In: Mazzaferri EL, Samaan N, editors, Endocrine tumors. Cambridge: Blackwell Scientific Publications, Inc.; 1993 p. 278-333
5. Massin JP, Savoie JC, Garnier H, et al. Pulmonary metastases in differentiated thyroid carcinoma. Study of 58 cases with implications for the primary tumor treatment. Cancer 1984;53:982-92
6. Baudin E, Travagli JP, Ropers J, et al. Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer 1998;83(3):553-9
7. Moosa M, Mazzaferri EL. Occult thyroid carcinoma. Cancer J 1997;10:180-8
8. Tourniaire J, Bernard MH, Bizollon-Roblin MH, et al. Papillary microcarcinoma of the thyroid. 179 cases reported since 1973 Presse Med 1998;27(29):1467-9
9. Hay ID, Grant CS, Bergstralh EJ, et al. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery 1998;124:958-66
10. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16(2):109-41
11. Hay ID, Bergstralh EJ, Grant CS, et al. Impact of primary surgery on outcome in 300 patients with pathologic tumor-node-metastasis stage III papillary thyroid carcinoma treated at one institution from 1940 through 1989 Surgery 1999;126(6):1173-81
12. Mazzaferri EL, Young RL. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. AmJ Med 1981;70:511-8
13. Samaan NA, Maheshwari YK, Nader S, et al. Impact of therapy for differentiated carcinoma of the thyroid: an analysis of 706 cases. J Clin Endocrinol Metab 1983;56:1131-8
14. Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940 - 1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 2002;26(8):879-85
15. Bilimoria KY, Bentrem DJ, Ko CY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 2007;246(3):375-81
16. Frankenthaler RA, Sellin RV, Cangir A, Goepfert H. Lymph node metastasis from papillary-follicular thyroid carcinoma in young patients. Am J Surg 1990;160:341-3
17. Haveman JW, Van Tol KM, Rouwe CW, et al. Surgical experience in children with differentiated thyroid carcinoma. Ann Surg Oncol 2003;10(1):15-20
18. Kouvaraki MA, Shapiro SE, Fornage BD, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 2003;134(6):946-54
19. White ML, Gauger PG, Doherty GM. Central lymph node dissection in differentiated thyroid cancer. World J Surg 2007;31(5):895-904
20. Scheumann GF, Gimm O, Wegener G, et al. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg 1994;18(4):559-67
21. Tisell LE, Nilsson B, Molne J, et al. Improved survival of patients with papillary thyroid cancer after surgical microdissection. World J Surg 1996;20(7):854-9
22. Hughes CJ, Shaha AR, Shah JP, Loree TR. Impact of lymph node metastasis in differentiated carcinoma of the thyroid: a matched-pair analysis. Head Neck 1996;18(2):127-32
23. McHenry CR, Rosen IB. Walfish PG. Prospective management of nodal metastases in differentiated thyroid cancer. Am J Surg 191;162:353-7
24. Cheah WK, Arici C, Ituarte PH, et al. Complications of neck dissection for thyroid cancer. World J Surg 2002;26(8):1013-6
25. Henry JF, Gramatica L, Denizot A, et al. Morbidity of prophylactic lymph node dissection in the central neck area in patients with papillary thyroid carcinoma. Langenbecks Arch Surg 1998;383(2):167-9
26. Sosa JA, Bowman HM, Tielsch JM, et al. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 1998;228:320-8
27. Kozak OV, Muzichenko LV, Trembach AM, et al. First treatment activity and outcome of radioiodine therapy in thyroid cancer patients with metastases in lymph nodes: mathematical correlation and clinical implications. Exp Oncol 2006;28(1):75-9
28. Machens A, Hinze R, Thomusch O, Dralle H. Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 2002;26(1):22-8
29. Wada N, Suganuma N, Nakayama H, et al. Microscopic regional lymph node status in papillary thyroid carcinoma with and without lymphadenopathy and its relation to outcomes. Langenbecks Arch Surg 2007;392(4):417-22
30. Ito Y, Tomoda C, Uruno T, et al. Preoperative ultrasonographic examination for lymph node metastasis: usefulness when designing lymph node dissection for papillary microcarcinoma of the thyroid. World J Surg 2004;28(5):498-501
31. Musacchio MJ, Kim AW, Vijungco JD, Prinz RA. Greater local recurrence occurs with 'berry picking' than neck dissection in thyroid cancer. Am Surg 2003;69(3):191-6
32. Gemsenjager E, Perren A, Seifert B, et al. Lymph node surgery in papillary thyroid carcinoma. J Am Coll Surg 2003;197(2):182-90
33. Kim ES, Kim TY, Koh JM, et al. Completion thyroidectomy in patients with thyroid cancer who initially underwent unilateral operation. Clin Endocrinol (Oxf) 2004;61(1):145-8
34. Pasieka JL, Thompson NW, McLeod MK, et al. The incidence of bilateral well-differentiated thyroid cancer found at completion thyroidectomy. World J Surg 1992;16(4):711-6
35. De Jong SA, Demeter JG, Lawrence AM, Paloyan E. Necessity and safety of completion thyroidectomy for differentiated thyroid carcinoma. Surgery 1992;112:734-7
36. Maxon HR, Englaro EE, Thomas SR, et al. Radioiodine-131 therapy for well-differentiated thyroid cancer - a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med 1992;33:1132-6
37. Scheumann GFW, Seeliger H, Musholt TJ, et al. Completion thyroidectomy in 131 patients with differentiated thyroid carcinoma. Eur J Surg 1996;162:677-84
38. Udelsman R, Lakatos E, Ladenson P. Optimal surgery for papillary thyroid carcinoma. World J Surg 1996;20:88-93
39. Vassilopoulou-Sellin R, Klein MJ, Smith TH, et al. Pulmonary metastases in children and young adults with differentiated thyroid cancer. Cancer 1993;71:1348-52
40. Spencer CA, Takeuchi M, Kazarosyan M, et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998;83:1121-7
41. Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006;16(12):1229-42
42. Tsang RW, Brierley JD, Simpson WJ, et al. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 1998;82(2):375-88
43. Edmonds CJ, Hayes S, Kermode JC, Thompson BD. Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine. Br J Radiol 1977;50:799-807
44. Leboeuf R, Perron P, Carpentier AC, et al. L-T3 preparation for whole-body scintigraphy: a randomized-controlled trial. Clin Endocrinol (Oxf) 2007;67(6):839-44
45. Duntas LH, Biondi B. Short-term hypothyroidism after levothyroxine-withdrawal in patients with differentiated thyroid cancer: clinical and quality of life consequences. Eur J Endocrinol 2007;156(1):13-9
46. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metal 1999;84:3877-85
47. Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006;91(3):926-32
48. Robbins RJ, Driedger A, Magner J. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid 2006;16(11):1121-30
49. Pilli T, Brianzoni E, Capoccetti F, et al. A comparison of 1850 MBq (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant TSH-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 2007;92:3542-6
50. Hanscheid H, Lassmann M, Luster M, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 2006;47(4):648-54
51. Borget I, Corone C, Nocaudie M, et al. Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal. Eur J Endocrinol 2007;156(5):531-8
52. Mernagh P, Campbell S, Dietlein M, et al. Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective. Eur J Endocrinol 2006;155(3):405-14
53. Borget I, Remy H, Chevalier J, et al. Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen. Eur J Nucl Med Mol Imaging 2008;35:1457-63
54. Maxon HR, Boehringer TA, Drilling J. Low iodine diet in I-131 ablation of thyroid remnants. Clin Nucl Med 1983;8:123-6
55. Pluijmen MJ, Eustatia-Rutten C, Goslings BM, et al. Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2003;58(4):428-35
56. Costa A, Testori OB, Cenderelli C, et al. Iodine content of human tissues after administration of iodine containing drugs or contrast media. J Endocrinol Invest 1978;1(3):221-5
57. Medvedec M. Thyroid stunning in vivo and in vitro. Nucl Med Commun 2005;26(8):731-5
58. Morris LF, Waxman AD, Braunstein GD. Thyroid stunning. Thyroid 2003;13(4):333-40
59. Muratet JP, Giraud P, Daver A, et al. Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma. J Nucl Med 1997;38:1362-8
60. Cholewinski SP, Yoo KS, Klieger PS, O'Mara RE. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 1311. J Nucl Med 2000;41(7):1198-202
61. Urhan M, Dadparvar S, Mavi A, et al. Iodine-123 as a diagnostic imaging agent in differentiated thyroid carcinoma: a comparison with iodine-131 post-treatment scanning and serum thyroglobulin measurement. Eur J Nucl Med Mol Imaging 2007;34(7):1012-7
62. Tuttle RM, Leboeuf R, Robbins RJ, et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med 2006;47(10):1587-91
63. Bal C, Padhy AK, Jana S, et al. Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer 1996;77(12):2574-80
64. Doi SA, Woodhouse NJ. Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer. Clin Endocrinol (Oxf) 2000;52(6):765-73
65. Van Nostrand D, Atkins F, Yeganeh F, et al. Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. Thyroid 2002;12(2):121-34
66. Brierley J, Maxon HR. Radioiodine and external radiation therapy. In: Fagin JA, editor, Thyroid cancer. Boston/Dordrecht London: Kluwer Academic Publishers; 1998 p. 285-317
67. Sherman SI, Tielens ET, Sostre S, et al. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 1994;78:629-34
68. Souza Rosario PW, Barroso AL, Rezende LL et al. Post I-131 therapy scanning in patients with thyroid carcinoma metastases: an unnecessary cost or a relevant contribution? Clin Nucl Med 2004;29(12):795-8
69. Pons F, Carrio I, Estorch M, et al. Lithium as an adjuvant of iodine-131 uptake when treating patients with well-differentiated thyroid carcinoma. Clin Nucl Med 1987;8:644-7
70. 131I therapy of metastatic, well differentiated thyroid carcinoma. J Clin Endocrinol Metab 1999;84:912-6
71. Datz FL. Cerebral edema following iodine-131 therapy for thyroid carcinoma metastatic to the brain. J Nucl Med 1986;27:637-40
72. DiRusso G, Kern KA. Comparative analysis of complications from I-131 radioablation for well-differentiated thyroid cancer. Surgery 1994;116:1024-30
73. Brown AP, Chen J, Hitchcock YJ, et al. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 2008;93(2):504-15
74. Rubino C, De Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003;89(9):1638-44
75. Kloos RT, Duvuuri V, Jhiang SM, et al. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. J Clin Endocrinol Metab 2002;87(12):5817-20
76. Cooper DS, Specker B, Ho M, et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 1998;8(9):737-44
77. McGriff NJ, Csako G, Gourgiotis L, et al. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 2002;34(7-8):554-64
78. Biondi B, Fazio S, Carella C, et al. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1993;77:334-8
79. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994;331(19):1249-52
80. Toivonen J, Tahtela R, Laitinen K, et al. Markers of bone turnover in patients with differentiated thyroid cancer with and Following withdrawal of thyroxine suppressive therapy. Eur J Endocrinol 1998;138:667-73
81. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med 1995;332:767-73
82. Marcocci C, Golia F, Vignali E, Pinchera A. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine. J Bone Miner Res 1997;12:72-7
83. Eustatia-Rutten CF. Smit JW, Romijn JA, et al. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol (Oxf) 2004;61(1):61-74
84. Chiovato L, Latrofa F, Braverman LE, et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med 2003;139(5 Pt 1):346-51
85. Bachelot A, Leboulleux S, Baudin E, et al. Neck recurrence from thyroid carcinoma: serum thyroglobulin and high-dose total body scan are not reliable criteria for cure after radioiodine treatment. Clin Endocrinol (Oxf) 2005;62(3):376-9
86. Torlontano M, Crocetti U, Augello G, et al. Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy. J Clin Endocrinol Metab 2006;91(1):60-3
87. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88(4):1433-41
88. Schlumberger M, Berg G, Cohen O, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 2004;150(2):105-12
89. Pacini F, Molinaro E, Castagna MG, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 2003;88(8):3668-73
90. Noguchi S, Yamashita H, Murakami N, et al. Small carcinomas of the thyroid - a long-term follow-up of 867 patients. Arch Surg 1996;131:187-91
91. Kloos RT, Mazzaferri EL. A single recombinant human thyrotrophin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 2005;90(9):5047-57
92. Schlumberger M, Mancusi F, Baudin E, Pacini F. 131-I Therapy for elevated thyroglobulin levels. Thyroid 1997;7:273-6
93. Van Tol KM, Jager PL, De Vries EG, et al. Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin. Eur J Endocrinol 2003;148(6):589-96
94. Pacini F, Agate L, Elisei R, et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic 131-I whole body scan: comparison of patients treated with high 131-I activities versus untreated patients. J Clin Endocrinol Metab 2001;86(9):4092-7
95. Kabasakal L, Selcuk NA, Shafipour H, et al. Treatment of iodine-negative thyroglobulin-positive thyroid cancer: differences in outcome in patients with macrometastases and patients with micrometastases. Eur J Nucl Med Mol Imaging 2004;31(11):1500-4
96. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86(4):1447-63
97. Schlumberger M, Challeton C, De Vathaire F, et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 1996;37:598-605
98. Chin BB, Patel P, Cohade C, et al. Recombinant human thyrotropin stimulation of fluoro-d-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 2004;89(1):91-5
99. Xing M, Westra WH, Tufano RR et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2006;90(12):6373-9
100. Jhiang SM, Caruso DR, Gilmore E, et al. Detection of the PTC/retTPC oncogene in human thyroid cancers. Oncogene 1992;7:1331-7
101. Ito Y, Arai K, Nozawa R, et al. S100A10 expression in thyroid neoplasms originating from the follicular epithelium: contribution to the aggressive characteristic of anaplastic carcinoma. Anticancer Res 2007;27(4C):2679-83
102. Min HS, Choe G, Kim SW, et al. S100A4 expression is associated with lymph node metastasis in papillary microcarcinoma of the thyroid. Mod Pathol 2008;21(6):748-55